 Anakinra, Kinnaret registered trademark symbol, is an interleukin, one receptor antagonist, Illinois, one Ra, FDA approved for use in rheumatoid arthritis and neonatal onset multi-system inflammatory disease. It has shown efficacy for numerous dermatologic conditions, including hydrodinitis suprativa, Bechet's disease, Muckelwell syndrome and SAFO syndrome. Anakinra is a promising option in the treatment of difficult-to-treat dermatologic inflammatory conditions refractory to first-line therapies, but further and higher quality data is needed to clarify its therapeutic role. This article was authored by Carl Teckmeyer, Junkalo Atassi, Jeffrey Jow and others.